Compare Genworth Financial Inc Common Stock (GNW) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genworth Financial Inc Common Stock vs Viatris Inc — how do they compare? Genworth Financial Inc Common Stock trades at $8.82 (market cap $3.36B), while Viatris Inc trades at $17.56 (market cap $19.81B). The key difference: Viatris Inc is far larger — about 5.9× Genworth Financial Inc Common Stock's market cap, and Viatris Inc pays a 2.78% dividend while Genworth Financial Inc Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Genworth Financial Inc Common Stock for 0 Days and Viatris Inc for 57 Days on average.
| GNW | VTRS | |
|---|---|---|
Market Cap | $3.36B | $19.81B |
Volume | 3,333,156 | 7,547,542 |
Sector | Financials | Health |
52-Week High | $10.60 | $18.27 |
52-Week Low | $7.94 | $9.98 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $2.87B | $31.92B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Genworth Financial (GNW) trades at $8.89, down 1.77% today, with neutral technical signals and mixed fundamental performance. The company maintains stable revenue around $7.1-7.2B but faces margin pressure, with net income declining from $223M to $212M year-over-year. Recent Q2 2026 earnings beat expectations at $0.29 EPS, while the company expanded its share repurchase program by $500M in September 2026.
GNW presents value characteristics with low P/B (0.38) and P/S (0.49) ratios, but weak profitability metrics (ROE 2.42%) and analyst caution (70.59% hold rating) suggest limited near-term catalysts. Key risks include legacy insurance liabilities and competitive pressures, while the upcoming Q3 earnings on November 4 could provide directional clarity.
Viatris (VTRS) trades at $17.44, down 0.57% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of $3.51B in 2025. Recent news highlights include FDA approval for WAKIX in Japan and recognition as a top employer. Analyst consensus is mixed with a $22.17 price target representing 27% upside potential.
The stock presents a value opportunity with reasonable P/S and P/B ratios, but faces fundamental challenges including negative profit margins and high debt. Positive cash flow generation and consistent earnings beats provide support, while competitive pressures and execution risks remain concerns for investors seeking turnaround potential in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Genworth Financial Inc Common Stock
Genworth Financial, Inc. is a holding company that provides products and services related to aging and long-term care planning, and is the parent company of publicly traded mortgage insurer Enact Holdings, Inc.
Read more on GNW →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
